PARP1 and ovarian cancer: Recently, olaparib, an agent that targets several PARP isoforms including PARP1, PARP2 and PARP3, has been approved for the treatment of ovarian cancer in patients harboring deleterious mutations of the BRCA1/2 genes [19, 20].